These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36070202)

  • 1. Remission of psoriatic arthritis 24 h after adalimumab therapy.
    Song S; Wan L; Xia P; Chen J
    Dermatol Ther; 2022 Nov; 35(11):e15807. PubMed ID: 36070202
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
    Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
    Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
    Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriatic arthritis.
    Durham LE; Taams LS; Kirkham BW
    Br J Hosp Med (Lond); 2016 Jul; 77(7):C102-8. PubMed ID: 27388392
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
    Schwartzman S; Li Y; Zhou H; Palmer JB
    Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E; Parsons WJ; Perrotta FM
    J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
    Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
    Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study.
    Lorenzin M; Ortolan A; de Hooge M; Frallonardo P; Piccoli A; Cozzi F; Oliviero F; Punzi L; Ramonda R
    Int J Immunopathol Pharmacol; 2015 Dec; 28(4):479-87. PubMed ID: 26384393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
    Soubrier M; Pereira B; Frayssac T; Abdi D; Couderc M; Daron C; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Clin Exp Rheumatol; 2016; 34(6):1059-1064. PubMed ID: 27607233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database.
    Oelke KR; Chambenoit O; Majjhoo AQ; Gray S; Higgins K; Hur P
    J Comp Eff Res; 2019 Jun; 8(8):607-621. PubMed ID: 30912454
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    J Rheumatol; 2018 Jan; 45(1):78-82. PubMed ID: 28966209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection.
    Atteno M; Costa L; Matarese A; Caso F; Del Puente A; Cantarini L; Bocchino ML; Sanduzzi A; Scarpa R
    Clin Rheumatol; 2014 Apr; 33(4):543-7. PubMed ID: 24554385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model.
    da Silva MRR; Dos Santos JBR; Almeida AM; Alvares-Teodoro J; Acurcio FA
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):473-479. PubMed ID: 33474995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
    Cárdenas M; de la Fuente S; Font P; Castro-Villegas M; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérez J; Escudero-Contreras A; Casado M; Del Prado J; Collantes-Estévez E
    Rheumatol Int; 2016 Feb; 36(2):231-41. PubMed ID: 26494567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.
    Aaltonen K; Heinonen A; Joensuu J; Parmanne P; Karjalainen A; Varjolahti-Lehtinen T; Uutela T; Puurtinen-Vilkki M; Arstila L; Blom M; Sokka T; Nordström D
    Semin Arthritis Rheum; 2017 Jun; 46(6):732-739. PubMed ID: 28010883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.